PCPeyton E. Conrey

Peyton E. Conrey

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Peyton E. Conrey has a total of 193 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Aberrant STAT signaling drives T cell dysregulation in a targetable pediatric sepsis endotype

    by Robert B. Lindell, Samir Sayed, Jose S. Campos, Montana Knight, Andrea A. Mauracher, Ceire A. Hay, Peyton E. Conrey, Julie C. Fitzgerald, Nadir Yehya, Stephen T. Famularo, et al.

    Sepsis is a leading cause of morbidity and mortality in critically ill children, yet heterogeneity in immune responses complicates the development of targeted therapies. Although immune dysregulation is associated with poor outcomes in sepsis, it remains unclear which host immune factors contribute causally to sepsis morbidity and mortality. To address this gap, we integrated deep immune phenotyping, plasma proteomics, single-cell transcriptomics, and phosphoflow cytometry in a prospective cohort of 88 critically ill children to elucidate the immunologic mechanisms which underly disease heterogeneity. Unsupervised clustering of plasma cytokines identified three immunologic subgroups, including a high-severity group (“Group C”) characterized by marked hypercytokinemia, driven primarily by IL-6 and IFN-γ. Group C exhibited distinct alterations in immune cell frequency and activation status, along with a strong association between hyperinflammatory signaling and lymphocyte dysfunction. Single-cell RNA sequencing revealed transcriptional signatures of T cell activation and metabolic stress, and identified widespread suppression of a lymphoid protective gene program across CD8⁺ T cell subsets. In the setting of increased expression of activation markers, T cell receptor repertoire analysis revealed no dominant clonotypes, consistent with a bystander mechanism of T cell activation. Using phosphoflow cytometry, we demonstrated baseline hyperactivation of STAT1 and STAT3 in CD8⁺ T cells from patients in Group C, and these cells failed to respond to aCD3/aCD28 stimulation. Together, these findings define IL-6/IFN-γ–driven T-cell dysfunction as a distinct endotype of immune dysregulation in pediatric sepsis, highlighting the JAK/STAT axis as a potential future target for immunomodulatory therapy.

  • Open Access

    The immunopathological landscape of human pre-TCRα deficiency: From rare to common variants

    by Marie Materna, Ottavia M. Delmonte, Marita Bosticardo, Mana Momenilandi, Peyton E. Conrey, Bénédicte Charmeteau-De Muylder, Clotilde Bravetti, Rebecca Bellworthy, Axel Cederholm, Frederik Staels, et al.

    We describe humans with rare biallelic loss-of-function PTCRA variants impairing pre–α T cell receptor (pre-TCRα) expression. Low circulating naive αβ T cell counts at birth persisted over time, with normal memory αβ and high γδ T cell counts. Their TCRα repertoire was biased, which suggests that noncanonical thymic differentiation pathways can rescue αβ T cell development. Only a minority of these individuals were sick, with infection, lymphoproliferation, and/or autoimmunity. We also report that 1 in 4000 individuals from the Middle East and South Asia are homozygous for a common hypomorphic PTCRA variant. They had normal circulating naive αβ T cell counts but high γδ T cell counts. Although residual pre-TCRα expression drove the differentiation of more αβ T cells, autoimmune conditions were more frequent in these patients compared with the general population.


  • IgA deficiency destabilizes homeostasis toward intestinal microbes and increases systemic immune dysregulation

    by Peyton E. Conrey, Lidiya Denu, Kaitlin C. O’bOyle, Isaiah Rozich, Jamal Green, Jeffrey Maslanka, Jean-Bernard Lubin, Tereza Duranova, Brittany L. Haltzman, Lauren Gianchetti, et al.

    The ability of most patients with selective immunoglobulin A (IgA) deficiency (SIgAD) to remain apparently healthy has been a persistent clinical conundrum. Compensatory mechanisms, including IgM, have been proposed, yet it remains unclear how secretory IgA and IgM work together in the mucosal system and, on a larger scale, whether the systemic and mucosal anti-commensal responses are redundant or have unique features. To address this gap in knowledge, we developed an integrated host-commensal approach combining microbial flow cytometry and metagenomic sequencing (mFLOW-Seq) to comprehensively define which microbes induce mucosal and systemic antibodies. We coupled this approach with high-dimensional immune profiling to study a cohort of pediatric patients with SIgAD and household control siblings. We found that mucosal and systemic antibody networks cooperate to maintain homeostasis by targeting a common subset of commensal microbes. In IgA-deficiency, we find increased translocation of specific bacterial taxa associated with elevated levels of systemic IgG targeting fecal microbiota. Associated features of immune system dysregulation in IgA-deficient mice and humans included elevated levels of inflammatory cytokines, enhanced follicular CD4 T helper cell frequency and activation, and an altered CD8 T cell activation state. Although SIgAD is clinically defined by the absence of serum IgA, the symptomatology and immune dysregulation were concentrated in the SIgAD participants who were also fecal IgA deficient. These findings reveal that mucosal IgA deficiency leads to aberrant systemic exposures and immune responses to commensal microbes, which increase the likelihood of humoral and cellular immune dysregulation and symptomatic disease in patients with IgA deficiency.


  • Open Access

    Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared with adult and pediatric COVID-19

    by Laura A. Vella, Josephine R. Giles, Amy E. Baxter, Derek A. Oldridge, Caroline Diorio, Leticia Kuri-Cervantes, Cécile Alanio, Maria Betina Pampena, Jennifer E. Wu, Zeyu Chen, et al.

    MIS-C is defined by lymphocyte activation, including elevated plasmablast frequencies and marked activation of CX3CR1 + CD8 + T cells.